Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OncoTherad
- Development stage
- Phase 2
- Lead developer
- Universidade Estadual de Campinas
- Modality
- Nanoparticles → Drug Delivery Systems
- Administration
- Intravesical, Intramuscular
01
Overview
OncoTherad is a **nanostructured inorganic phosphate complex associated with a glycosidic protein** developed at the University of Campinas, Brazil, as a novel immunotherapy particularly for non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG)[1][3][6]. It is a **nanoimmunotherapy** designed to activate the innate immune system predominantly through **Toll-like receptor 4 (TLR4)**, leading to enhanced interferon signaling and potent activation of cytotoxic CD8+ T cells, decreased immune checkpoints (notably PD-1/PD-L1), and reversal of immunosuppression in the bladder tumor microenvironment[3][4][5][6]. OncoTherad has demonstrated significant efficacy and safety in early-phase clinical trials for BCG-unresponsive NMIBC, with substantial rates of complete pathological response and recurrence-free survival, and is notable for its immune-mediated antitumor effect through multiple mechanisms[3][4][5].
- Brand names
- OncoTherad
- Other names
- nanostructured complex CFI-1MRB-CFI-1MRB-CFI1MRB-CFI 1
02
Targets
FOXP3 (Forkhead box protein P3)RANKL (Receptor Activator for Nuclear Factor-kappa B Ligand)TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)CD274 (Programmed cell death protein 1 ligand 1)PDCD1 (Programmed cell death protein 1 receptor)TNFRSF11A (RANK)
Beyond the preview
Go deeper on OncoTherad.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OncoTherad.